SEC Company Response from AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) (AYTU) — Apr 1, 2016
AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
Date: April 1, 2016 · CIK: 0001385818 · Accession: 0001144204-16-092202
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-53121
Referenced dates: March 28, 2016
Letter
VIA EDGAR Division of Corporation Finance Preliminary Proxy Statement on Schedule 14A Filed March 15, 2016 File No. 000-53121
Re: Aytu BioScience, Inc.
Dear Ms. Hayes:
Aytu BioScience, Inc. (“Aytu”) provides this letter in response to the comment of the Staff of the Securities and Exchange Commission (the “Commission”) with respect to the above-captioned filing, as set forth in the Staff’s comment letter dated March 28, 2016. Aytu filed revised preliminary proxy materials on March 30, 2016 in response to the comments of the Commission.
Aytu acknowledges that:
· Aytu is responsible for the adequacy and accuracy of the disclosure in the filing;
· Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and
· Aytu may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
AYTU BIOSCIENCE, INC.
/s/ Gregory A. Gould
Gregory A. Gould
Chief Financial Officer
Show Raw Text
CORRESP
1
filename1.htm
April 1, 2016
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, DC 20549
Attn: Suzanne Hayes
Re: Aytu BioScience, Inc.
Preliminary Proxy Statement on Schedule
14A
Filed March 15, 2016
File No. 000-53121
Dear Ms. Hayes:
Aytu BioScience, Inc. (“Aytu”)
provides this letter in response to the comment of the Staff of the Securities and Exchange Commission (the “Commission”)
with respect to the above-captioned filing, as set forth in the Staff’s comment letter dated March 28, 2016. Aytu filed revised
preliminary proxy materials on March 30, 2016 in response to the comments of the Commission.
Aytu acknowledges that:
· Aytu is responsible for the adequacy and accuracy of the disclosure
in the filing;
· Staff comments or changes to disclosure in response to Staff comments
do not foreclose the Commission from taking any action with respect to the filing; and
· Aytu may not assert Staff comments as a defense in any proceeding
initiated by the Commission or any person under the federal securities laws of the United States.
AYTU BIOSCIENCE, INC.
/s/ Gregory A. Gould
Gregory A. Gould
Chief Financial Officer